Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Tishcon Receives Orphan Drug Designations for CoQ10
May 24, 2004
1 Min Read
Tishcon Receives Orphan Drug Designations for CoQ10
WESTBURY, N.Y.On April 12, theFood and Drug Administration (FDA) granted Tishcon Corp. Orphan Drug Designationfor ubiquinol (coenzyme Q10) in the treatment of pediatric congestive heartfailure and in Huntingtons disease. Tishcon (www.tishcon.com) previouslyreceived the status for CoQ10 for treatment of mitochondrial cytopathies.
You May Also Like